Failure Assessment (SOFA) of two or more extracerebral organ systems, and 44% showed worsening organ dysfunction over the first 72 hours after ROSC [1] . A few recent studies have found that the severity of organ dysfunction determined by SOFA score and the Acute Physiology and Chronic Health Evaluation (APACHE) II score were associated with in-hospital mortality in patients after cardiac arrest [4] [5] [6] [7] [8] . However, in patients who receive targeted temperature management (TTM), data are lacking on whether these disease severity scores are associated with good neurological outcome, which is the ultimate treatment goal for patients resuscitated after OHCA. Moreover, early identification of good neurological outcome is helpful to physicians so that valuable medical resources and management such as extracorporeal membrane oxygenation (ECMO) or coronary artery bypass graft can be appropriately allocated.
Therefore, in the present study, the initial APACHE II score was calculated based on the data collected immediately after ROSC rather than within 24 hours after being admitted to the intensive care unit (ICU). We investigated the association between initial APACHE II score and good neurological outcome in comatose survivors of OHCA who were treated with TTM. 
MAtErIALS And MEtHodS

Study Design
Data Collection and Definitions
The collected data included patient demographic information (including age and sex), comorbid conditions, all variables necessary for computing APACHE II scores, and Cerebral Performance Category (CPC) score on day 28.
Initial APACHE II score was calculated based on the data collected immediately after ROSC rather than within 24 hours of admission to the ICU. The primary outcome was good neurological one, defined as CPC 1 or 2 on day 28. CPC 1 indicates good cerebral performance (able to work and normal life); CPC 2, moderate cerebral disability (disabled but independent); CPC 3, severe cerebral disability (conscious but disabled and dependent); CPC 4, comatose or in a persistent vegetative state (unconsciousness); CPC 5, brain death/dead [9] . CPC scores were divided into good (CPC 1 or 2) neurological outcome and poor (CPC 3, 4, or 5) neurological outcome, which are accepted categorizations for evaluating post-cardiac arrest patients [10] . 
Statistical Analysis
rESuLtS
During the study period, 143 patients received TTM after cardiac arrest; 62 patients (43.4%) survived, and 34 (23.8%) had good neurological outcomes on day 28. Table 1 27.62 ± 6.16, P = 0.001). Serum lactic acid, C-reactive protein, and creatinine levels showed significant differences between these two groups ( Table 2 ).
The predictive ability of the initial APACHE II score for good neurological outcome assessed using the AUROC The APACHE II score was first introduced in 1985 by Knaus et al. [11] as a method for assessing disease severity. Currently, the APACHE II score is the most widely used method for predicting mortality in ICU patients. Although the APACHE II score is known to be useful for predicting morbidity and mortality in patients after cardiac arrest [8, 12] , to the best of our knowledge, only a few previous studies specifically validated its use in OHCA survivors who received TTM. Donnino et al. [8] evaluated the APACHE II score in a population of post-cardiac arrest patients, including cases of both in-hospital cardiac arrest and OHCA, and found that the initial APACHE II score in OHCA patients was a modest predictor of poor neurological outcome (AUC = 0.58). However, in the present study, an AUROC of 0.697 was found, indicating better predictive power. This result may be due to differences in the study population because 46% of patients were not treated with TTM. Moreover, our results may be a better reflection of real-world outcomes in patients who receive TTM [13, 14] . In North America and Europe, patients expected to have bad neurological outcome are allowed to have life-supporting treatment withdrawn; thus, the longterm neurological outcome of these patients is unknown.
In contrast, in South Korea, a legal prohibition exists against the withdrawal of life-supporting treatment from resuscitated patients. As such, all patients who are resuscitated, even those with poor neurological outcome, receive conservative care until death in the hospital, which allowed us to determine the patients' neurological outcomes. 
